Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.46 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL595184 | 0.87 | ALDH1A1 (0.54) | DGAT1PDE4AALDH1A1KDM4EMCHR1 | |
| SCHEMBL892196 | 0.86 | MCHR1 (0.54) | KDM4EMCHR1NPC1RAB9AMAPT | |
| SCHEMBL28630464 | 0.85 | CYP1A2 (0.49) | ALDH1A1KDM4EMEN1KMT2AL3MBTL1 | |
| SCHEMBL3054689 | 0.85 | MCHR1 (0.42) | DGAT1ALDH1A1KDM4EMCHR1NPC1 | |
| SCHEMBL14050010 | 0.84 | ALDH1A1 (0.51) | DGAT1PDE4AALDH1A1KDM4EMCHR1 | |
| SCHEMBL3904940 | 0.77 | GAA (0.50) | ALDH1A1KDM4EMEN1KMT2ARAB9A | |
| SCHEMBL2063655 | 0.77 | NPC1 (0.61) | ALDH1A1KDM4EMCHR1NPC1RAB9A | |
| SCHEMBL899098 | 0.76 | NPC1 (0.59) | DGAT1PDE4AALDH1A1KDM4EMEN1 | |
| SCHEMBL902999 | 0.76 | P2RX1 (0.57) | DGAT1ALDH1A1KDM4EMAPTHPGD | |
| SCHEMBL5860864 | 0.75 | FFAR1 (0.46) | ALDH1A1KDM4EMCHR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576532-B1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX LLC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-9663483-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC | 2016-01-28 | — | — | US | disclosed |
| CN-103108868-B | Furyl compounds and uses thereof | NOVOMEDIX, LLC (US) | 2015-11-25 | — | — | CN | disclosed |
| US-9149527-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2015-10-06 | — | — | US | disclosed |
| CN-104860907-A | Furanyl compounds and the use thereof | NOVOMEDIX LLC | 2015-08-26 | — | — | CN | disclosed |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8722731-B2 | Furanyl compounds and the use thereof | NOVOMEDIX, LLC (US) | 2014-05-13 | — | — | US | disclosed |
| CN-103108868-A | Furyl compounds and uses thereof | NOVOMEDIX LLC | 2013-05-15 | — | — | CN | disclosed |
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2576532-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | Novomedix, LLC (US) | 2013-04-10 | — | — | EP | disclosed |
| WO-2011156321-A9 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011156321-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | NOVOMEDIX, LLC (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116317-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, EIF4A1 | DGAT1 3432/4885PDE4A 2159/4885ALDH1A1 2149/4885 |
| US-20160024040-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | DGAT1 3272/4885PDE4A 2108/4885ALDH1A1 2350/4885 |
| US-20140309297-A1 | FURANYL COMPOUNDS AND THE USE THEREOF | EIF4EBP1, EIF4E, GLI1 | DGAT1 3272/4885PDE4A 2108/4885ALDH1A1 2350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.